AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination with Ivonescimab plus chemotherapy as first-line therapy in adult subjects with HER2 negative、advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

Trial Details

NCT ID
NCT06196697
Phase
PHASE2
Sponsor
Harbin Medical University
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Cadonilimab
  • Ivonescimab
  • XELOX
  • SOX
Locations (sample)
  • Harbin, China|45.75,126.65

Key Eligibility Criteria

  • Males or females aged ≥ 18 to ≤ 75 years at the time of signing informed consent.
  • Imaging examination confirmed unresectable locally advanced or metastatic gastric cancer (GC) or gastroesophageal binding cancer (GEJC), and histop…
  • Subjects have not received prior systemic therapy for locally advanced or metastatic gastric adenocarcinoma or adenocarcinoma of the gastroesophage…
  • HER2 is negative. HER2 negative is defined as: IHC 0/1+, or IHC 2+ and FISH/ISH negative (HER2: CEP17 ratio \<2). FISH can be replaced by locally a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →